Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of “Moderate Buy” by Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA) has received an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $8.1429.

Several equities analysts have commented on the stock. Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Monday, December 29th. Zacks Research upgraded shares of Sana Biotechnology from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Bank of America lifted their target price on Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, Citizens Jmp upped their target price on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research report on Thursday, October 30th.

Institutional Trading of Sana Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the business. TD Waterhouse Canada Inc. purchased a new position in shares of Sana Biotechnology during the third quarter worth about $37,000. LRI Investments LLC purchased a new position in shares of Sana Biotechnology in the 4th quarter valued at approximately $41,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Sana Biotechnology during the third quarter worth approximately $36,000. Foguth Wealth Management LLC. purchased a new position in Sana Biotechnology in the 4th quarter valued at $44,000. Finally, Lyell Wealth Management LP acquired a new position in Sana Biotechnology in the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Trading Up 10.7%

Shares of SANA stock opened at $3.93 on Monday. The company has a market cap of $1.05 billion, a P/E ratio of -4.05 and a beta of 1.96. The firm has a fifty day moving average price of $4.54 and a 200 day moving average price of $4.13. Sana Biotechnology has a 12 month low of $1.26 and a 12 month high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. On average, equities analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.